The number of COVID-19 vaccination doses administered in India rose to 2206672631 as of Oct 27 2023. This dataset includes a chart with historical data for India Coronavirus Vaccination Total.

The Indian state of Utter Pradesh reported the highest number of administered doses of the vaccine against the coronavirus (COVID-19) as of November 13, 2023. Furthermore, over 2.2 billion total vaccine doses were administered in India during the same time period.

Vaccination in India were administered since January 16, 2021, with the administration of vaccines to all health care workers in the first phase. In February, the vaccination program was expanded to cover front line workers. The second phase of the program began in March which included citizens above the age of 60 and subsequently, people above the age of 45 with comorbidities. India’s vaccination program currently includes two vaccines, namely, Oxford University – AstraZeneca’s Covidshield vaccine, manufactured by the Serum Institute of India and Bharat Biotech Covaxin. Russia's Sputnik V was expected to be added to the mix starting May 2021.

India administered over 2.2 billion vaccine doses for the coronavirus (COVID-19) as of October 20, 2022. The number of people infected with the virus was declining across the Asian country. With the onset of the second wave since late March 2021, the central government increased funding to boost vaccination production.

The number of COVID-19 vaccination doses administered per 100 people in India rose to 156 as of Oct 27 2023. This dataset includes a chart with historical data for India Coronavirus Vaccination Rate.

A survey from 2019 to 2021 in India revealed that the share of children under six years who had received immunizations was highest for Hindu children, with over 55 percent. On the other hand, the share of Jain children under six years receiving immunization was over 36 percent in India.

Note: In these datasets, a person is defined as up to date if they have received at least one dose of an updated COVID-19 vaccine. The Centers for Disease Control and Prevention (CDC) recommends that certain groups, including adults ages 65 years and older, receive additional doses.

On 6/16/2023 CDPH replaced the booster measures with a new “Up to Date” measure based on CDC’s new recommendations, replacing the primary series, boosted, and bivalent booster metrics The definition of “primary series complete” has not changed and is based on previous recommendations that CDC has since simplified. A person cannot complete their primary series with a single dose of an updated vaccine. Whereas the booster measures were calculated using the eligible population as the denominator, the new up to date measure uses the total estimated population. Please note that the rates for some groups may change since the up to date measure is calculated differently than the previous booster and bivalent measures.

This data is from the same source as the Vaccine Progress Dashboard at https://covid19.ca.gov/vaccination-progress-data/ which summarizes vaccination data at the county level by county of residence. Where county of residence was not reported in a vaccination record, the county of provider that vaccinated the resident is included. This applies to less than 1% of vaccination records. The sum of county-level vaccinations does not equal statewide total vaccinations due to out-of-state residents vaccinated in California.

These data do not include doses administered by the following federal agencies who received vaccine allocated directly from CDC: Indian Health Service, Veterans Health Administration, Department of Defense, and the Federal Bureau of Prisons.

Totals for the Vaccine Progress Dashboard and this dataset may not match, as the Dashboard totals doses by Report Date and this dataset totals doses by Administration Date. Dose numbers may also change for a particular Administration Date as data is updated.

Previous updates:

• On March 3, 2023, with the release of HPI 3.0 in 2022, the previous equity scores have been updated to reflect more recent community survey information. This change represents an improvement to the way CDPH monitors health equity by using the latest and most accurate community data available. The HPI uses a collection of data sources and indicators to calculate a measure of community conditions ranging from the most to the least healthy based on economic, housing, and environmental measures.

• Starting on July 13, 2022, the denominator for calculating vaccine coverage has been changed from age 5+ to all ages to reflect new vaccine eligibility criteria. Previously the denominator was changed from age 16+ to age 12+ on May 18, 2021, then changed from age 12+ to age 5+ on November 10, 2021, to reflect previous changes in vaccine eligibility criteria. The previous datasets based on age 16+ and age 5+ denominators have been uploaded as archived tables.

• Starting on May 29, 2021 the methodology for calculating on-hand inventory in the shipped/delivered/on-hand dataset has changed. Please see the accompanying data dictionary for details. In addition, this dataset is now down to the ZIP code level.

Immunization, BCG (% of one-year-old children) in India was reported at 89 % in 2023, according to the World Bank collection of development indicators, compiled from officially recognized sources. India - Immunization, BCG (% of one-year-old children) - actual values, historical data, forecasts and projections were sourced from the World Bank on August of 2025.

Total people vaccinated against Covid in India, March, 2023 The most recent value is 1030000000 total people vaccinated as of March 2023, no change compared to the previous value of 1030000000 total people vaccinated. Historically, the average for India from January 2021 to March 2023 is 729161439 total people vaccinated. The minimum of 3758843 total people vaccinated was recorded in January 2021, while the maximum of 1030000000 total people vaccinated was reached in September 2022. | TheGlobalEconomy.com

Note: In these datasets, a person is defined as up to date if they have received at least one dose of an updated COVID-19 vaccine. The Centers for Disease Control and Prevention (CDC) recommends that certain groups, including adults ages 65 years and older, receive additional doses.

Starting on July 13, 2022, the denominator for calculating vaccine coverage has been changed from age 5+ to all ages to reflect new vaccine eligibility criteria. Previously the denominator was changed from age 16+ to age 12+ on May 18, 2021, then changed from age 12+ to age 5+ on November 10, 2021, to reflect previous changes in vaccine eligibility criteria. The previous datasets based on age 12+ and age 5+ denominators have been uploaded as archived tables.

Starting June 30, 2021, the dataset has been reconfigured so that all updates are appended to one dataset to make it easier for API and other interfaces. In addition, historical data has been extended back to January 5, 2021.

This dataset shows full, partial, and at least 1 dose coverage rates by zip code tabulation area (ZCTA) for the state of California. Data sources include the California Immunization Registry and the American Community Survey’s 2015-2019 5-Year data.

This is the data table for the LHJ Vaccine Equity Performance dashboard. However, this data table also includes ZTCAs that do not have a VEM score.

This dataset also includes Vaccine Equity Metric score quartiles (when applicable), which combine the Public Health Alliance of Southern California’s Healthy Places Index (HPI) measure with CDPH-derived scores to estimate factors that impact health, like income, education, and access to health care. ZTCAs range from less healthy community conditions in Quartile 1 to more healthy community conditions in Quartile 4.

The Vaccine Equity Metric is for weekly vaccination allocation and reporting purposes only. CDPH-derived quartiles should not be considered as indicative of the HPI score for these zip codes. CDPH-derived quartiles were assigned to zip codes excluded from the HPI score produced by the Public Health Alliance of Southern California due to concerns with statistical reliability and validity in populations smaller than 1,500 or where more than 50% of the population resides in a group setting.

These data do not include doses administered by the following federal agencies who received vaccine allocated directly from CDC: Indian Health Service, Veterans Health Administration, Department of Defense, and the Federal Bureau of Prisons.

For some ZTCAs, vaccination coverage may exceed 100%. This may be a result of many people from outside the county coming to that ZTCA to get their vaccine and providers reporting the county of administration as the county of residence, and/or the DOF estimates of the population in that ZTCA are too low. Please note that population numbers provided by DOF are projections and so may not be accurate, especially given unprecedented shifts in population as a result of the pandemic.

Out of the two billion COVID-19 vaccines administered, over 1.6 billion vaccines were Covishield vaccine developed by Oxford university and AstraZeneca as of September 1, 2022 in India. Vaccinations in India were administered since January 16, 2021, with the administration of vaccines to all health care workers in the first phase. In February, the vaccination program was expanded to cover front line workers. The second phase of the program began in March which included citizens above the age of 60 and subsequently, people above the age of 45 with comorbidities. India’s vaccination program currently includes three vaccines, namely, Oxford University – AstraZeneca’s Covishield vaccine, manufactured by the Serum Institute of India, Bharat Biotech Covaxin and Russia's Sputnik V.

In 2023, the share of BCG vaccination coverage in India was ** percent. Meanwhile, the lowest share of BCG vaccination coverage was seen in 1981 with only **** percent. The figure reflects a clear increase immunization coverage trend with an increase in time.

India Exports of human or animal blood, antisera and other blood fractions, vaccines, toxins to United States was US$71.53 Million during 2024, according to the United Nations COMTRADE database on international trade.

Immunization, HepB3 (% of one-year-old children) in India was reported at 91 % in 2023, according to the World Bank collection of development indicators, compiled from officially recognized sources. India - Immunization, HepB3 (% of one-year-old children) - actual values, historical data, forecasts and projections were sourced from the World Bank on August of 2025.

Snapshot img

Vaccines Market Size 2025-2029

The vaccines market size is forecast to increase by USD 160.22 billion at a CAGR of 23.1% between 2024 and 2029.

The market is experiencing significant growth, driven by increased funding for research and development, leading to the launch of new vaccines. One of the most promising trends in this market is the development of nanoparticle vaccines, which offer enhanced immunogenicity and improved delivery systems. This trend is particularly evident in the development of nanoparticle vaccines, which offer enhanced efficacy and safety. However, the high cost of research, development, and manufacturing poses a significant challenge for market players. Examples include the inactivated polio vaccine (IPV) and influenza vaccine. These costs can be attributed to the complex production processes involved in vaccine creation, as well as the need for rigorous clinical trials to ensure safety and efficacy. 
However, the high cost of vaccine research, development, and manufacturing remains a significant challenge for market participants. Despite this, the market presents numerous opportunities for companies seeking to capitalize on the growing demand for vaccines, particularly in emerging economies with rising healthcare expenditures. Strategic partnerships, collaborations, and acquisitions are key strategies for companies looking to navigate the competitive landscape and stay ahead of the curve.
Overall, the market is poised for continued growth, with significant opportunities for innovation and investment in the coming years. Companies that can effectively address the challenges of cost and regulatory compliance while delivering high-quality, effective vaccines will be well-positioned to succeed.

What will be the Size of the Vaccines Market during the forecast period?

Request Free Sample

The market driven by the continuous development of immunization programs and the pursuit of vaccine equity. Immunological memory, antibody response, and cost-effectiveness analysis are key factors influencing market growth. Vaccine supply chain, efficacy testing, preservation, patent, and licensing are essential aspects of the market. Nanotechnology and universal vaccines are emerging trends, aiming to improve vaccine accessibility and quality control. Vaccine manufacturing, regulatory approval, and economic impact are crucial elements in the market, with intellectual property, vaccine shelf life, and vaccine development pipeline being significant factors.
Vaccine innovation and vaccine safety monitoring are essential for addressing disease burden and ensuring potency, stability, and sterility. Vaccine logistics and vaccine stability are critical for successful distribution and administration, while vaccine safety monitoring emphasizes the importance of ongoing surveillance and immune response assessment. 

How is this Vaccines Industry segmented?

The vaccines industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD million' for the period 2025-2029, as well as historical data from 2019-2023 for the following segments.

Type

  Subunit vaccines
  Live attenuated vaccines
  Inactivated vaccines
  Toxoid vaccines
  Others


End-user

  Hospitals
  Clinics


Technology

  mRNA vaccines
  Viral vector vaccines
  Protein based vaccines
  DNA vaccines
  Others


Route Of Administration

  Intramuscular
  Subcutaneous
  Oral
  Intranasal
  Others


Disease Type

  Influenza
  Human papillomavirus
  Hepatitis
  Measles
  mumps
  rubella
  Others


Age Group

  Pediatric
  Adult
  Adolescent
  Geriatric


Geography

  North America

    US
    Canada


  Europe

    France
    Germany
    Italy
    UK


  APAC

    China
    India
    Japan


  South America

    Brazil


  Rest of World (ROW)

By Type Insights

The subunit vaccines segment is estimated to witness significant growth during the forecast period.

Subunit vaccines, integral components of the healthcare system's disease prevention strategy, employ specific antigenic pieces of a pathogen, such as proteins, sugars, or capsids, to induce a robust immune response. These vaccines, including the mRNA vaccines, are designed to target specific components of the pathogen, making them highly effective in preventing infections. The development process involves identifying and isolating these antigenic components, followed by formulation and rigorous testing to ensure safety and efficacy. For instance, in the realm of disease outbreak prevention, a phase 3 trial for the subunit TB vaccine candidate M72/AS01E was initiated in March 2024 in South Africa.

This trial aims to evaluate the vaccine's efficacy in preventing the progression from latent TB to active pulmonary TB, contributing to herd immunity and ultimately, disease surveillance and vaccine distribution within the healthcare s

From April to June 2021, the state of Uttar Pradesh had the highest Polio immunizations administered, with approximately *** thousand infants vaccinated. Bihar and Maharashtra followed with around *** thousand and around *** thousand infants vaccinated in the same time duration.

The herd immunity threshold for selected global diseases as of 2013 can be found here.

Additional file 1. Master chart in Excel.

India Exports of human or animal blood, antisera and other blood fractions, vaccines, toxins to Colombia was US$22.29 Million during 2024, according to the United Nations COMTRADE database on international trade.

India Imports of human or animal blood, antisera and other blood fractions, vaccines, toxins from Guatemala was US$1.38 Thousand during 2022, according to the United Nations COMTRADE database on international trade.

India reported almost 45 million cases of the coronavirus (COVID-19) as of October 20, 2023, with more than 44 million recoveries and about 532 thousand fatalities. The number of cases in the country had a decreasing trend in the past months.

Burden on the healthcare system

With the world's second largest population in addition to an even worse second wave of the coronavirus pandemic seems to be crushing an already inadequate healthcare system. Despite vast numbers being vaccinated, a new variant seemed to be affecting younger age groups this time around. The lack of ICU beds, black market sales of oxygen cylinders and drugs needed to treat COVID-19, as well as overworked crematoriums resorting to mass burials added to the woes of the country. Foreign aid was promised from various countries including the United States, France, Germany and the United Kingdom. Additionally, funding from the central government was expected to boost vaccine production.

Situation overview
Even though days in April 2021 saw record-breaking numbers compared to any other country worldwide, a nation-wide lockdown has not been implemented. The largest religious gathering - the Kumbh Mela, sacred to the Hindus, along with election rallies in certain states continue to be held. Some states and union territories including Maharashtra, Delhi, and Karnataka had issued curfews and lockdowns to try to curb the spread of infections.

India Exports of human or animal blood, antisera and other blood fractions, vaccines, toxins to Laos was US$1.87 Million during 2024, according to the United Nations COMTRADE database on international trade.